| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
12,072 | 6,017 | 520 | 644 | 787 |
|
Cost of Revenue
|
-540 | -500 | -582 | -583 | -463 |
|
Gross Profit
|
11,532 | 5,517 | -62 | 61 | 324 |
|
Selling, General and Administrative Expenses
|
-33,989 | -23,127 | -10,182 | -9,271 | -10,640 |
|
Research and Development Expenses
|
-3,511 | -3,511 | -3,659 | -2,942 | -4,262 |
| Depreciation, Amortization and Depletion
|
-10 | -- | -24 | -117 | -181 |
|
Operating Income/Expenses
|
-35,733 | -26,638 | -13,841 | -12,330 | -15,083 |
|
Total Operating Profit/Loss
|
-24,201 | -21,121 | -13,903 | -12,269 | -14,759 |
| Total Net Finance Income/Expense
|
-194,811 | -195,820 | -17 | 257 | -834 |
| Net Investment Income
|
191,110 | 188,178 | 2,178 | 3,241 | 2,271 |
| Irregular Income/Expenses
|
-41,438 | -12,127 | 0 | -159 | -757 |
|
Other Income/Expense, Non-Operating
|
526 | -- | 203 | 80 | 7 |
|
Non-Operating Income/Expenses, Total
|
-133,071 | -19,769 | 2,161 | 3,419 | 687 |
|
Pretax Income
|
-157,272 | -40,890 | -11,742 | -8,850 | -14,072 |
|
Provision for Income Tax
|
0 | 0 | 0 | 0 | 0 |
|
Net Income from Continuing Operations
|
-157,272 | -40,890 | -11,742 | -8,850 | -14,072 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-157,272 | -40,890 | -11,742 | -8,850 | -14,072 |
|
Net Income after Non-Controlling/Minority Interests
|
-157,272 | -40,890 | -11,742 | -8,850 | -14,072 |
|
Net Income Available to Common Stockholders
|
-157,272 | -40,890 | -11,742 | -8,850 | -14,072 |
|
Diluted Net Income Available to Common Stockholders
|
-157,272 | -40,890 | -11,742 | -8,850 | -14,072 |
| Basic EPS
|
53.74 | -1.85 | -3.28k | -10.92k | -39.10k |
| Diluted EPS
|
53.74 | -1.85 | -3.28k | -10.92k | -39.10k |
|
Basic Weighted Average Shares Outstanding
|
61,141.3660 | 22,047.8410 | 3.5770 | 0.8110 | 0.3600 |
|
Diluted Weighted Average Shares Outstanding
|
61,141.3660 | 22,047.8410 | 3.5770 | 0.8110 | 0.3600 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-157,204 | -40,255 | -11,725 | -9,107 | -13,238 |
|
EBITDA
|
-157,204 | -40,255 | -11,725 | -8,945 | -12,983 |
|
Normalized EBITDA
|
-750,970 | -745,688 | -12,184 | -10,409 | -12,253 |
|
Normalized Income
|
-751,038 | -746,323 | -12,201 | -10,314 | -13,342 |
|
Total Unusual Items
|
-593,766 | -705,433 | -459 | -1,464 | 730 |
12/31/2022 - 6/27/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade